NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received European Patent EP3752831, related to contextualizing fingerprint chemical analysis with fingerprint deposition volume. The grant marks the Company's eighth European patent, further enhancing intellectual property rights around its fingerprint sweat drug testing technol ...

Core Viewpoint - Grail's stock experienced a significant increase of up to 12.4% following a rating upgrade from a Wall Street analyst, despite a price target reduction from $110 to $65, which still represents a 39% premium over the recent closing price [1][2]. Company Performance - Grail's current stock price is $46.73, with a market capitalization of $1.9 billion. The stock has seen a 52-week range from $20.44 to $118.84, indicating high volatility [3]. - The company faced challenges this year after failing to meet the primary endpoint in a landmark trial for its Galleri test, which aimed to detect Stage III-IV cancers [3][4]. Trial Results - The trial results indicated a substantial increase in the detection of Stage I-II cancers and a clinically meaningful reduction in Stage IV diagnoses compared to standard care, although the reduction in combined Stage III and IV detections was not statistically significant [6][7]. - There is optimism that follow-up data from the trial may support the efficacy of the Galleri test, potentially aiding in gaining FDA approval and insurance coverage [5]. Analyst Sentiment - The upgrade from TD Cowen reflects a belief in the potential of Grail's stock, suggesting it is a buy at the current price, which aligns with the positive sentiment from investors following the rating change [8].

Core Insights - Grail's stock (NASDAQ: GRAL) experienced a significant decline of 45.6% in February due to disappointing results from its Galleri multicancer screening test conducted with the NHS in England [1][5] Test Results and Implications - The Galleri test, which involved a demographic of 142,000 people over three years, failed to meet its primary endpoint of demonstrating a statistically significant reduction in Stage III-IV cancers [2] - Although the test identified a substantial increase in the absolute number of Stage I-II cancers, this did not lead to a statistically significant decrease in Stage III and IV detections, complicating potential insurance coverage [4][7] - The failure to meet the primary endpoint raises concerns about the likelihood of receiving FDA approval and insurer reimbursement for the Galleri test [5] Investor Sentiment and Future Outlook - Despite the negative results, there is a potential for optimism among investors who may view the stock as mispriced based on risk/reward considerations [6] - The CEO of Grail indicated that the trial design could have been improved and suggested that follow-up data might provide more insights into the efficacy of the Galleri test [8]

Core Insights - BillionToOne (BLLN) reported $96.05 million in revenue for the quarter ended December 2025, showing no year-over-year change, with an EPS of $0.11 compared to $0 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $85.85 million by +11.89%, and the EPS surpassed the consensus estimate of $0.07 by +69.23% [1] Financial Performance - Total tests delivered were 170,000, slightly below the average estimate of 172,644 based on two analysts [4] - The overall average selling price (ASP) was $561.00, exceeding the two-analyst average estimate of $484.19 [4] - Revenue from Prenatal services was $86.1 million, higher than the three-analyst average estimate of $75.37 million [4] - Revenue from Oncology services reached $9.1 million, compared to the $8.82 million average estimate based on three analysts [4] - Revenue from Clinical Trial Support and Other Services was $0.8 million, below the $1.28 million average estimate based on three analysts [4] Market Performance - Shares of BillionToOne have returned +0.5% over the past month, while the Zacks S&P 500 composite has decreased by -1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Cannabix Technologies Inc. and Omega Laboratories Inc. have published a peer-reviewed study validating a breath testing technology for detecting recent marijuana use, marking a significant advancement in cannabis testing methods [1][2][8]. Group 1: Study and Technology Validation - The study published in the Journal of Analytical Toxicology demonstrates the accuracy of Omega Laboratories' method for detecting cannabinoids in breath samples collected using Cannabix's Breath Collection Unit [2][8]. - The breath-based testing system provides a reliable, non-invasive solution for identifying recent cannabis consumption, addressing limitations of traditional testing methods that often detect historical use [2][6]. - The validation study confirms the effectiveness of the Cannabix Breath Collection Unit (BCU) and its ability to simultaneously quantify multiple cannabinoids, including Δ9-THC, Δ8-THC, CBD, and CBN [14][15]. Group 2: Strategic Partnership and Development - In May 2024, Cannabix and Omega entered a strategic partnership to enhance the design of the BCU and the laboratory testing method, leading to significant improvements over 20 months [3][11]. - The partnership has resulted in a robust laboratory method that is quicker and simpler than previous approaches, achieving improved detection sensitivity and precision [14]. Group 3: Market Relevance and Applications - With the expansion of medical and recreational marijuana use, the ability to detect recent cannabis use has become increasingly important for workplace drug testing, drug treatment facilities, and road safety programs [6][11]. - The breath testing method correlates with blood detection windows, assisting in identifying cannabis use within the last 4 hours prior to sample collection [6][9]. - The Cannabix BCU is positioned as a stable, portable tool for breath collection, offering a quick and non-invasive method for testing [15]. Group 4: Future Developments and Marketing - Cannabix is ramping up manufacturing of the BCU and Breath Collection Kits to meet anticipated demand for breath-based cannabis testing solutions [11]. - The company has extended a marketing agreement with Black Swan Solutions Inc. to enhance its digital marketing efforts, including social media content and online campaigns [13].

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $17.3 million, a modest 3% increase year-over-year compared to $16.8 million in Q4 2024 [19] - Full year revenue for 2025 was $69.6 million, reflecting a transitional period for the top line [7][20] - Biopharma revenue was $10.9 million in Q4 2025, down from $12.2 million in Q4 2024, while full year biopharma revenue was $49 million compared to $51 million in 2024 [20] - Clinical revenue recognized was $0.9 million in Q4 2025, up from $0.2 million in Q4 2024, and $2 million for the full year 2025 compared to $0.8 million in 2024 [21] - Gross margin was 11% in Q4 2025 and 22.7% for the full year, with expectations of margin dilution continuing into 2026 [22][23] Business Line Data and Key Metrics Changes - The company delivered 6,183 clinical tests in Q4 2025, representing a 41% sequential growth and a 329% increase year-over-year [6] - For the full year 2025, over 16,000 clinical tests were delivered, growing 394% over 2024 [6] - MRD biopharma revenue grew nearly 240% over 2024, indicating strong demand for the strategic MRD offering [7][20] Market Data and Key Metrics Changes - The clinical market for MRD testing is expected to mature into a $20-plus billion opportunity, with Personalis well-positioned to capture a significant share [5] - The company achieved two Medicare coverage decisions for breast and lung cancer, validating the value of its technology [12] Company Strategy and Development Direction - The company is focused on scaling its MRD strategy, with expectations to quadruple clinical volumes in 2026 [10] - The strategic roadmap includes expanding relationships with biopharma companies and increasing the number of oncologists ordering tests [11][16] - The introduction of the Real-Time Variant Tracker report is aimed at enhancing the clinical utility of the NeXT Personal test [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong underlying demand for MRD testing and the potential for significant revenue growth in 2026, with guidance of $78 million to $80 million [10][27] - The company is navigating a planned decline in revenue from legacy contracts while building a diversified and sustainable high-growth engine [20] - Management highlighted the importance of ongoing clinical evidence generation to support reimbursement initiatives and technology development [24][100] Other Important Information - The company ended Q4 2025 with cash and short-term investments of $240 million and no debt, allowing for continued investment in growth strategies [25][26] - Operating expenses for Q4 2025 were $27.2 million, up from $22.7 million in Q4 2024, primarily due to increased commercial and R&D expenses [24] Q&A Session Summary Question: How does the recent reimbursement affect the focus of reps internally and externally? - Management indicated that reimbursement provides legitimacy in discussions with physicians and key opinion leaders, enhancing the company's position in the market [30][32] Question: Are there any pushouts or cancellations of contracts in the biopharma sector? - Management noted that the sector is stabilizing, with no significant pushouts or jolts to the business, and they are making progress in MRD [36][39] Question: What is the expected mix of reimbursed versus non-reimbursed indications in 2026? - Approximately 20% of tests are expected to come from breast cancer, 15%-20% from lung cancer, and 20% from immuno-oncology, with the remainder from other indications [46] Question: What are the expectations for adjuvant reimbursement in breast and lung cancer? - Management is focused on driving hard to submit for coverage for neoadjuvant breast cancer and colorectal cancer this year, but exact timelines are dependent on publication acceptance [95]

Core Insights - Veracyte, Inc. (VCYT) reported fourth-quarter 2025 adjusted earnings of 53 cents per share, a 47.2% increase year-over-year, exceeding the Zacks Consensus Estimate by 30.06% [1] - The company's GAAP earnings per share were 52 cents, compared to 7 cents in the same period last year [1] - For the full year 2025, EPS reached $1.78, marking a 49.6% increase from the previous year and surpassing estimates by 6.2% [1] Revenue Performance - Revenues for Q4 2025 increased by 18.5% year-over-year to $140.6 million, beating the Zacks Consensus Estimate by 1.4% [2] - Total revenues for 2025 were reported at $517.1 million, a 16% increase from the prior year, also surpassing estimates by 0.4% [2] - Following the earnings announcement, VCYT shares rose by 1.9% in after-hours trading [2] Segmental Revenue Breakdown - Testing revenues reached $135.8 million, up 21.1% year-over-year, driven by growth in Decipher and Afirma revenues of 27% and 16%, respectively [3] - Total testing volume was approximately 45,500, reflecting a 16% increase compared to the prior year [3] - Product revenues increased by 27% year-over-year to $3 million in Q4 [3] Margin Analysis - Total cost of revenues was $36 million, a decrease of 3% year-over-year [5] - Gross profit rose by 28.3% to $104.7 million, with gross margin expanding by 568 basis points to 74.4% [5] - Selling and marketing expenses increased by 4.5% to $25.9 million, while general and administrative expenses decreased by 35.5% to $17 million [5] Cash and Capital Structure - Veracyte ended Q4 2025 with cash and cash equivalents of $362.6 million, up from $239.1 million at the end of 2024 [6] - Cumulative net cash from operating activities was $136.3 million, compared to $75.1 million a year ago [6] Future Guidance - The company reiterated its 2026 revenue guidance of $570 million to $582 million, indicating a growth of 10-13%, with testing revenues expected to grow by 14-16% [8] - The adjusted EBITDA margin is projected to be 25% for 2026 [8] Overall Performance Assessment - Veracyte's fourth-quarter performance showed earnings and revenues exceeding estimates, supported by strong growth in the core testing business [9] - The company has seen a steady pipeline of account wins in Affirma and increased utilization per account, continuing into Q4 [9] - The transition of all Afirma volume to a more scalable, lower-cost platform and record growth in Decipher orders are positive indicators for future performance [10]

Core Insights - Intelligent Bio Solutions Inc. has successfully received and deployed its first shipment of Intelligent Fingerprinting Drug Screening Readers through a partnership with Syrma Johari, marking a significant step in scaling production capacity and validating the operational and financial benefits of the collaboration [1][3] - The partnership is expected to deliver annual production cost savings of over 40%, leading to an anticipated improvement of approximately 20 percentage points in gross margin annually [1][3] - The company has doubled its in-house production capacity for lateral flow test strips, enhancing vertical integration and accelerating research and development [1][4] Production and Manufacturing - The first shipment of readers is being deployed across key customer verticals such as construction, transportation, logistics, and manufacturing in the U.K. and Europe, supporting growing commercial demand [2] - The partnership with Syrma Johari has provided access to manufacturing capacity approximately four times greater than prior capabilities, allowing for accelerated fulfillment and cost savings [3] - The company has sourced advanced manufacturing equipment that has doubled its in-house production capacity for lateral flow test strips, improving margins and reducing lead times [4] Strategic Positioning - The successful deployment of the first shipment and increased production capacity positions the company to enter the U.S. market with operational strength and the ability to grow with demand [5] - The company is building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion and accelerates innovation [5] - Additional production shipments are expected throughout 2026 as the company continues to build inventory and expand its commercial footprint [5] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [6] - The system is designed to screen for recent drug use in workplace settings, providing results in under ten minutes, which is valuable for employers in safety-critical industries [6] - Current customer segments outside the U.S. include construction, manufacturing, transport, logistics, mining, drug treatment organizations, and coroners [6]

Core Viewpoint - 20/20 BioLabs has launched its OneTest for Longevity, a blood test that integrates inflammatory biomarkers, dietary habits, and scientific research to provide personalized health insights, utilizing IBM's watsonx.ai technology [1][2][3] Group 1: Product Launch and Features - The OneTest for Longevity solution calculates and displays an individual's risk of chronic diseases such as diabetes, dementia, and cardiovascular disease, offering personalized dietary recommendations based on biomarker levels [2] - The platform leverages IBM's advanced AI capabilities, including the Granite 4.0 foundation models and the Docling toolkit, to analyze nutritional research and deliver evidence-based health insights [3][6] - The test is available for purchase and is conducted in CLIA-licensed and CAP-accredited labs, although it has not sought FDA approval [3][7] Group 2: Partnerships and Technology - 20/20 BioLabs has partnered with DAISource to enhance its AI-enabled health solutions, aiming to improve public health through scalable and secure technology [3] - IBM's role is as an information technology provider, focusing on supporting enterprises with secure workloads in various sectors, including healthcare [4] Group 3: Company Background and Market Position - 20/20 BioLabs is an early market leader in laboratory-based blood tests for early detection and prevention of cancers and chronic diseases, with its stock listed on Nasdaq under the ticker symbol "AIDX" since February 19, 2026 [5][6] - The company also operates a Clinical Laboratory Innovation Accelerator (CLIAx) to assist overseas diagnostics startups in launching lab tests in the U.S. [8]

Core Insights - Intelligent Bio Solutions Inc. (INBS) has partnered with Bouygues UK to deploy its fingerprint drug testing technology across 13 project sites, marking a shift from third-party testing to an in-house solution that emphasizes hygiene, efficiency, and cost savings [1][3][4] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat for drug use [5] - The company aims to revolutionize portable testing in safety-critical industries, with applications in construction, manufacturing, transport, and more [5] Partnership Details - Bouygues UK, a subsidiary of Bouygues Construction, operates in over 50 countries and reported a turnover of €10.3 billion in 2024 [2] - The partnership is characterized as a collaborative relationship rather than a traditional supplier-customer dynamic, with both parties emphasizing mutual understanding and alignment with workplace safety culture [3][4] Operational Advantages - The transition to in-house drug testing is expected to provide Bouygues UK with greater control over the testing process, enhancing workplace hygiene and employee experience while also confirming substantial cost savings through ROI analysis [4] - The fingerprint drug testing technology has been validated for its operational advantages in high-stakes construction environments, reinforcing its economic viability for large-scale applications [4]